NeoGenomics (NEO) stock is soaring 5.24% in pre-market trading on Wednesday, following the release of its third-quarter earnings report and an analyst price target increase. The oncology-focused genetic testing company has captured investors' attention with its robust revenue growth despite widening losses.

According to the Q3 earnings report, NeoGenomics demonstrated strong revenue growth, signaling positive momentum in its core business. While the company's losses have increased, the market appears to be focusing on the top-line expansion, suggesting confidence in the company's long-term prospects.

Adding to the positive sentiment, TD Cowen has raised its price target for NeoGenomics from $12 to $14, indicating increased optimism about the company's future performance. However, it's worth noting that Benchmark Co. has maintained its Hold rating on the stock, suggesting a more cautious stance. The mixed analyst views highlight the complex landscape NeoGenomics is navigating as it pursues growth in the competitive genetic testing market.